Lexology June 21, 2024
Latham & Watkins LLP

Click here to listen to the audio

One of the year’s major drug pricing conferences just concluded in New Orleans. Join the Latham team to discuss takeaways from the conference, with topics including 340B developments, state legislative activity, and IRA implementation.

Current developments grabbed much of the spotlight when...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Conferences / Podcast, Govt Agencies, Health System / Hospital, Healthcare System, Pharma, Pharma / Biotech, Pricing / Spending, Provider, States, Trends
Related Articles:
CVS successfully converts commercial pharmacy contracts to “cost plus” model
Drug extends survival in lung cancer patients: J&J
Novo Nordisk Adds Obesity and Diabetes to AI Drug Research Pact With Flagship’s Valo Health
The Download: what’s next for AI, and stem-cell therapies
The first state to cover Ozempic under the ACA

Share This Article